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Abstract We report a retrospective review of 110 patients
with acute Guillain-Barre´ syndrome (GBS) admitted to a
specialised intensive care unit (ICU) in a tertiary referral
centre over a 25 year period, the start of which coincided
with the widespread introduction of plasma exchange (PE)
and intravenous immunoglobulin (IVIG). The results were
analysed by comparing 52 patients admitted in the first
decade (1991–2000; Group 1) with 58 patients admitted
between 2001–2014 (Group 2). Patients in both groups
were comparable with respect to age and sex, and had a
similar incidence and range of ICU complications. They
received a comparable range of immunomodulatory treat-
ments including IVIG and PE. However, the delay from
presentation to referral to the tertiary ICU was longer in
patients in Group 2. They also required mechanical venti-
lation for a longer duration, and had longer ICU and hos-
pital stays. In Group 2, there was a higher incidence of
axonal neuropathy (51%, compared to 24% in Group 1).
Despite the longer delay to referral, the prevalence of
axonal neuropathy and the duration of ventilation, overall
mortality showed a downward trend (Group 1: 13.5%;
Group 2: 5.2%). There was no late mortality in either group
after step-down to neuro-rehabilitation or following dis-
charge home or to the referring hospital. The rehabilitation
outcomes were similar. This data show a shift in the pattern
of referral to a tertiary referral ICU between the first and
second decades following the wider availability of IVIG
and PE for the treatment of GBS. The possible causes and
implications of these findings are discussed.
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Introduction
Several randomised controlled trials have established the
effectiveness of both plasma exchange (PE) and intra-
venous immunoglobulin (IVIG) in Guillain-Barre´ syn-
drome (GBS). Despite this approximately one third of
patients develop respiratory failure requiring tracheal
intubation and ventilatory support [1–7]. Many of these
patients also require intensive care because of profound
bulbar and limb weakness and autonomic instability.
The intensive care management of acute GBS has
evolved with the introduction of new modes of ventilation,
better techniques of supportive care and the widespread
availability of IVIG as a more convenient form of
immunomodulatory treatment than PE [8–10]. In the UK,
highly specialised neurological intensive care has become
easier to access with the development of neuroscience
centres, although there is considerable variation in the
provision of neurological support for patients admitted to
general ICUs. It remains uncertain whether these changes
have led to a significant change in the pattern of referral for
specialist care or an improvement in the management and
outcome of GBS.
In a previous study of 79 patients with acute GBS from the
neuromedical ICU (NMICU) at the National Hospital for
Neurology and Neurosurgery (NHNN) the overall mortality
was 5.1% although 15% remained severely disabled at
6 months and 10% at 1 year [11]. Several other large series
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of patients treated for GBS in ICUs have subsequently been
published. The mortality has varied from 6.5 to 12.2% but
there were significant differences in the severity and clinical
pattern of the cases seen and treated [12–15]. The majority of
patients died from the complications of intensive care and
prolonged immobility. Major complications, including
pneumonia, sepsis, pulmonary embolism and gastrointesti-
nal bleeding developed in 60% of intubated patients [16].
Approximately, 75% of patients will regain some degree of
mobility but slow recovery is well recognised particularly in
patients who develop ICU complications, require prolonged
ventilation or who have severe axonal loss. In one study [17]
the mortality at 1 year was 20% in the group that required
mechanical ventilation and recovery was delayed in a size-
able proportion of the survivors.
The long-term outcome of GBS requiring intensive care
not only reflects complications and mortality on the ICU.
In one study, although the mortality on ICU was 7.7%
acute hospital mortality occurring after discharge from ICU
was 16.7% [18], underlining the importance of step-down
care of patients with GBS. Other reports have also sug-
gested significant late mortality following discharge from
ICU [8, 12, 19, 20].
The histological features of GBS support a distinction
between acute inflammatory demyelinating polyneuropathy
(AIDP) and acute motor axonal polyneuropathy (AMAN)
or acute motor and sensory neuropathy (AMSAN), which
can be discriminated on nerve conduction studies [21–23].
However, there remains a considerable overlap and the
incidence of AIDP may be overestimated if the nerve
conduction studies are undertaken early in the course of the
disease. The most consistent prognostic features seem to be
age, severity of nadir and rapid deterioration to nadir. It is
unclear whether the histological type of GBS is relevant to
outcome although there remains a clinical view that the
prognosis for AMAN or secondary axonal loss in AIDP is
worse than isolated AIDP [24, 25].
The extensive and prolonged experience of neurological
ICU at The National Hospital for Neurology and Neuro-
surgery affords a unique opportunity to study long-term trends
in the referral patterns and outcome of patients with acute GBS
for specialist Neuro-Critical Care support. This retrospective
study spans a 25 year period, starting at the time when ran-
domised controlled trial evidence emerged for the effective-
ness of immunomodulatory treatment with PE and IVIG.
Methods
We divided adult patients seen on the specialist neu-
romedical ICU (Batten Harris unit) at the National Hospital
for Neurology and Neurosurgery into two cohorts: those
admitted in the years 1991–2000, and those admitted in
2001–2014. The first cohort overlaps with the previous
series published from this unit. We excluded cases subse-
quently found to have mimics of Guillain-Barre´ syndrome
including chronic inflammatory demyelinating polyneu-
ropathy. The primary reason for ICU admission, the pres-
ence of overt bulbar and autonomic dysfunction,
immunomodulatory treatment, and the need for and dura-
tion of mechanical ventilation were described, as was the
incidence of tracheostomy if indicated. In addition, patients
were classified into ‘early referrals’ if the interval between
onset of symptoms and arrival at ICU was \6 days and
‘late referrals’ if after this period.
Nerve conduction studies and electromyography were
performed on the ICU although electrical interference from
ventilatory and plasmapheresis equipment sometimes
restricted the procedure. When possible, limb temperature
was maintained at about 32 C. Sensory and motor con-
duction studies were typically performed using surface
electrodes on the median, ulnar, sural and common per-
oneal nerves of one side and often the superficial peroneal
and posterior tibial nerves as well. F-wave studies were
performed on motor nerves, but proximal stimulation at the
level of Erb’s point or the spinal column was not carried
out on the ICU. For sensory studies, amplitude, distal
latency and in most patients, sensory conduction velocities,
were recorded. Distal motor latencies, motor conduction
velocities and amplitudes of compound action potentials to
distal proximal stimulation were also measured. Concentric
needle electromyography was performed in general on a
proximal and a distal muscle of an upper and lower limb.
The baseline and follow-up electrodiagnostic studies
were reviewed and each patient was classified into elec-
trophysiological subtypes based on their initial study as
defined by Hadden et al. [22]. We determined whether
patients developed low compound muscle action potential
(CMAP) amplitudes (\20% lower limit of normal in at
least two nerves) or inexcitable nerves (CMAP absent in all
nerves or \10% lower limit of normal in one nerve and
absent in all other is tested) at any point during their illness.
Demyelination refers to patients with the features of AIDP.
These patients may later develop secondary axonal loss.
Axonal refers to presentation with AMAN or AMSAN.
All ICU complications were documented including
hyponatraemia (serum sodium \135 mmol/l) and abnor-
malities of liver function. Major morbidity was defined as
serious infection (ventilator acquired or aspiration pneu-
monia, sepsis), deep vein thrombosis, pulmonary embo-
lism, severe arrhythmia, haemodynamic instability,
gastrointestinal haemorrhage, complications of tra-
cheostomy, pseudomonas colitis due to clostridium diffi-
cile, ileus with or without bowel perforation and pain.
Outcome measures included length of stay (LOS) in the
ICU and the hospital; mortality in the ICU and in the
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hospital. Functional recovery was extracted from stan-
dardised collected assessments of Barthel score at dis-
charge in those patients undergoing rehabilitation at
NHNN. Data were not available for those patients under-
going rehabilitation elsewhere.
Values are expressed as mean ± SD or as median (in-
terquartile range). The Fisher exact test and the Kol-
mogorov–Smirnov test were used to compare across
cohorts for categorical and quantitative data, respectively.
Results
Group 1 (admitted 1991–2000) consisted of 52 patients
(mean 5.2 patients/year; 56% male) and Group 2
(2001–2014) included 58 patients (mean 4.5 patients/year;
62% male; Table 1). The mean age in Group 1 was
52 years (range 21–95) and in Group 2 48 years (range
15–82). There were seven deaths in Group 1 (13.5%) and
three in Group 2 (5.2%). The decrease in mortality did not
reach significance (Fisher exact test: p = 0.19). In Group
1, the most common cause of death was overwhelming
sepsis (four patients); other causes were blocked tra-
cheostomy, cardiogenic shock with bowel ischaemia, and
hypoxic-ischaemic brain injury. In Group 2, two patients
died of sepsis-related shock and one of cardiogenic shock.
Six patients in Group 1 were referred late, as opposed to
24 patients in Group 2 (Fisher exact test: p = 0.0005). The
mean length of ICU stay in Group 1 was 40 days (median
29) and in Group 2, 59 days (median 44). The distribution
of length of stay was, however, skewed with 12 patients
staying longer than 50 days in Group 1 and 26 in Group 2.
The longer stay for Group 2 was borderline-significant with
a Kolmogorov–Smirnov test (p = 0.051). The mean hos-
pital length of stay in Group 1 was 82 days (median 56)
and in Group 2, 108 days (median 103, p = 0.047) with 11
patients in Group 1 staying longer than 100 days compared
to 26 in Group 2.
In Group 1, three patients did not require tracheostomy
and were rapidly extubated. All the patients in Group 2
required tracheostomy.
The mean duration of ventilation was available for 37
patients in Group 1 and 42 patients in Group 2. In Group 1
it was 44 days (median 26 days; range 10–315) and in
Group 2, 59 days (median 54; range 12–253, p = 0.001).
All the patients in both groups were weaned from venti-
latory support before their transfer to step-down care,
rehabilitation or the referring hospital.
Nerve conduction studies showed that in Group 1, 38
(76%) cases were primarily demyelinating and 12 (24%)
axonal (2 unknown) whilst in Group 2, 28 (48%) were
primarily demyelinating and 30 (52%) axonal. Excluding
cases where the subtype was not established, the difference
in prevalence of axonal neuropathy was significant
(p = 0.006) (Fisher exact test).
We asked if the subtype of neuropathy correlated with
age or duration of ventilation. In Group 1, the mean ages
for demyelinating and axonal neuropathy subtypes were 54
and 44; the mean duration of ventilation was 37 vs.
48 days; and the mean length of hospital stay was 82 vs
88 days. In Group 2, the mean age for demyelinating and
axonal subtypes were 47 and 49, respectively; the mean
duration of ventilation was 45 vs. 74 days; and the mean
length of hospital stay was 86 vs 130 days. When Groups 1
and 2 were pooled, the duration of ventilation was signif-
icantly longer for patients with axonal neuropathy (Kol-
mogorov–Smirov test, p = 0.002).
There was no difference between the two cohorts with
regard to rehabilitation and gains made on Barthel score.
There was no late mortality between discharge from ICU and
from NHNN either home or to a referring hospital. None of
the patients required continuing non-invasive ventilatory
support. The place of discharge is shown in Table 1.
The antecedent precipitating factors are summarised in
Table 2. The incidence and nature of autonomic and sys-
temic complications during ICU care was similar with a high
frequency of pulse and blood pressure instability, bowel
disturbance, ventilator acquired pneumonia, hyponatraemia,
sepsis and tracheostomy complications (see Table 3).
Discussion
This retrospective study looked at referral patterns of
patients with severe GBS to a specialised neurological ICU
over a 25-year period. It has shown a striking change in
practice. Patients across the two described cohorts were of a
similar age and sex, had a similar incidence and range of ICU
complications and a comparable range of immunomodula-
tion treatment. However, patients admitted in the later
cohort, between January 2001 and December 2014, were
referred later in their illness, received mechanical ventilation
for a longer time, and required longer ICU and hospital stays.
In the latter group, there was a much higher incidence of
axonal neuropathy, possibly explaining the increased dura-
tion of ventilation and length of stay. There was also a non-
significant trend towards lower mortality despite a longer
duration of mechanical ventilation.
The data suggest that patients are increasingly referred
later in the course of the disease, when more profoundly
impaired as a result of respiratory muscle, bulbar and limb
weakness and dependency and with more severe axonal
forms of the condition. Despite the referral of more
severely impaired patients the ICU mortality was no
greater, there was no step-down mortality, and the dis-
charge outcome was unchanged.
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We speculate that in the earlier cohort patients were
transferred earlier in the course of the condition to a limited
number of specialist units able to provide PE. The
increasing use of IVIG as a first line treatment has meant
that most patients with Guillain-Barre´ syndrome are man-
aged in the ICU of the admitting hospital. Clinical expe-
rience suggests that this change in practice may extend to
the management of patients with severe acute Guillain-
Barre´ syndrome requiring ventilatory support. This means
that patients are transferred to specialist units only if their
condition fails to improve, if they continue to require
prolonged mechanical ventilation, or if they develop severe
complications of the primary condition. To some extent,
this change in practice may reflect the limited provision of
specialist Neurocritical care in the UK.
The study is necessarily limited because of its retro-
spective nature. The analysis is based on the review of
medical records originally completed by multiple different
observers although it should be emphasised that three of
the authors (NPH, RSH, DMK) were involved in the
Table 1 Demographic characteristics of the two patient groups
Group 1
1.1991–12.2000 (120 months)
Group 2
1.2001–12.2014 (156 months)
n 52 58
M:F 29:23 36:22
Age (years) mean (±SD) (median) (range) 52 (±19) (48) (21–95) 48(±18) (48) (15–82) NS
Time to referral [after onset (days)]\3 35 (76%) 23 (40%)
4–5 5 6
[6 6 (12%) 24 (41%) p = 0.0005
Unknown 6 5
NMICU stay (days) mean (±SD) (median) (range) 40 (±38) (29) (3–223) 59 (±54) (44) (8–263) p = 0.051
Hospital LOS (days) mean (±SD) (median) (range) 82 (±104) (56) (6–643) 108 (±83) (103) (11–424) p = 0.047
Intubated 51 58
Tracheostomy 49 58
Time to tracheostomy (days) 8 (±7) (1–39) 6 (±5) (1–33)
Duration of Ventilation Mean (± SD) (Median) (Range) 44 (±63) (26) (10–315) 59 (±47) (54) (12–253) p = 0.001
Neurophysiology
Demyelinating 38 (76%) 28 (48%)
Mean age (years) (±SD) (median) (range) 54 (±18) (54) (26–88) 47(±18) (48) (17–82)
Duration of ventilation Mean (±SD) (median) (range) 37 (±38) (20) (10–223) 45(±28) (45) (12–118)
Hospital LOS mean (±SD) (range) 82 (±111) (4–643) 86 (±41) (11–142)
Died 4 2
Axonal 12 (24%) 30 (51%)
Mean age (years) (±SD) (median) (range) 44 (±20) (38) (20–77) 49(±19) (52) (18 = 78)
Duration of ventilation mean (±SD) (median) (range) 48 (±38) (40) (6–115) 74(±58) (60) (13–253)
Hospital LOS mean (±SD) (range) 88(±85) (6–327) 130 (±102) (8–260)
Mortality
Died 3 1
Overall Treatment
Only Ig 40 (multiple: 5) 51 (multiple: 15)
Only PE 17 12
Both 12 12
Rehabilitation
n 30 32
Made gains on Barthel 29 30
Mean gain on Barthel 6.9 9.7
Barthel 18–20 on discharge 17/21 (81%) 27/32 (84%)
Discharged
Home 33 35
Another hospital 7 9
ICU 2 1
Long term care 1 1
Unknown 2
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management of all of the patients. The sample was inevi-
tably selected by the threshold for referring patients with
varying severity and the duration of disease from primary
to secondary or tertiary specialist units. The delays from
symptom onset to hospital admission, from hospital
admission to ICU transfer and from symptom onset to the
provision of IVIG were not always available, similarly,
when administered, the indication for first treatment with
IVIG in the referring hospital was not always clear. The
Barthel score at discharge was not available for all patients
in Group 1. The timing of nerve conduction studies in
relation to onset and the protocols used inevitably varied
considerably over the 24 years of the study, particularly as
many were undertaken in referring hospitals. We recognize
that the variable timing of neurophysiology studies will
have meant that some patients with inexcitable nerves may
have had an initial demyelinating neuropathy. Prospective
studies show that it can be difficult to classify the under-
lying neuropathy in 10–15% of patients. In this study, we
considered all patients with severe axonal loss at the time
of nerve conduction studies to have had a primary axonal
neuropathy but it is likely this would lead to an over-rep-
resentation of the axonal form in our results. Despite these
limitations, this study provides unique information about
changes in the pattern of referral to specialist ICU for GBS
in the UK over the past 25 years.
Delay in transferring patients with acute GBS to spe-
cialist ICU may occur for several reasons, including: wider
provision of primary general intensive care across the UK,
meaning that acutely ill patients are admitted, intubated
and ventilated sooner and appropriate treatment is com-
menced with the minimum delay; better acute management
and ICU care of Guillain-Barre´ syndrome in primary
ICUs;, improved neurological input to ICUs in general
hospitals; wider availability of IVIG and wider access to
neuro-rehabilitation facilities. More specialised ICU beds
also allow patients to be treated with high level medical
and nursing support for longer. The data suggest an
increased threshold for transferring patients to highly spe-
cialised units; this may be because of improved supportive
care in primary ICU and the more rapid and easier avail-
ability of immunomodulatory treatment.
The optimal management of severe AIDP and AMAN
remains uncertain and, in particular, the mechanisms and
management of patients who deteriorate after initial
improvement or continue to deteriorate after receiving first-
line immunomodulatory treatment is not clear. It is perhaps
these patients who should be transferred to specialised units
to allow a trial of repeated IVIG treatment or to consider the
role of combined plasma exchange followed by IVIG.
These findings raise a number of issues and concerns.
The change in practice in the UK suggested by this series,
is primarily likely to reflect increasing ICU provision,
better management guidelines and a wider availability of
neurological support. All these factors have probably led to
more patients remaining for longer periods in primary
ICUs without the need for transfer to specialist units.
Indeed the recent mortality data for ICU care of acute
Guillain-Barre´ syndrome in the UK, has been favourable
[18]. However, the acute hospital mortality data in other
series suggests an under-appreciation of the risks in step-
down care. The absence of any late mortality in this series,
following discharge from ICU, may reflect the availability
of continuing neurological support in a specialist hospital.
It is clear that future studies must seek to define more
clearly the indications, guidelines and timing of transfer
from general ICU to specialist neuroscience intensive care.
There is a debate about the place of highly specialised
neurological intensive care, and it is uncertain if their pri-
mary role should lie in managing patients with common
presentations of acute neurological disorders or if the scarce
resources should be focused on the specialised care of ter-
tiary referrals of the most complex and difficult management
Table 2 Antecedent factors precipitating acute Guillain-Barre´
syndrome
Group 1
1.1991–12.2000
Group 2
1.2001–12.2014
Campylobacter 13 8
Diarrhoea (culture negative) 6 6
Respiratory tract infection 12 15
CMV 2 1
Mycoplasma 1 2
Others 5 2
Table 3 ITU complications
1.1991–12.2000 1.2001–12.2014
Generalised autonomic
instability
43 38
Haemodynamic instability 31 31
Bowel disturbance (ileus, severe
constipation)
8 11
Percutaneous endoscopic
gastrostomy
2 2
Abnormal liver function 9 12
Hyponatraemia 7 8
Ventilator associated
pneumonia/aspiration
pneumonia
28 20
Sepsis 7 8
Tracheostomy complications 6 7
Uncontrolled severe pain 11 10
Urinary disturbance 12 9
Acute kidney injury 2 3
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problems, which often demand extensive time and resource
input to achieve the best outcomes. If this is the case it will be
impossible to prove such units improve the mortality and
morbidity rate of neurological disorders. However, they will
have an important role as centres of last resort and in
teaching, research and establishing guidelines of care.
In conclusion, the data presented in this paper argues
that the overall outcome of patients referred to a spe-
cialised ICU with Guillain-Barre´ syndrome has, at least,
remained stable despite referral of more severely affected
patients. Review of the recent literature indicates that the
failure to refer some severely affected patients to spe-
cialised units might contribute to the high acute hospital
mortality for the condition in the UK. This data argue
strongly for an improvement in the provision of Neuro-
critical care and earlier referral of patients with severe
acute Guillain-Barre´ syndrome in whom the need for pro-
longed mechanical ventilation is anticipated.
Compliance with ethical standards
Conflicts of interest There are no conflicts of interest.
Ethical standards The study was performed according to the ethical
standards statement.
Open Access This article is distributed under the terms of the
Creative Commons Attribution 4.0 International License (http://crea
tivecommons.org/licenses/by/4.0/), which permits unrestricted use,
distribution, and reproduction in any medium, provided you give
appropriate credit to the original author(s) and the source, provide a
link to the Creative Commons license, and indicate if changes were
made.
References
1. Ropper AH (1992) The Guillain-Barre´ syndrome. N Engl J Med
326(17):1130–1136
2. Rees JH, Gregson NA, Hughes RA (1995) Anti-ganglioside GM1
antibodies in Guillain-Barre´ syndrome and their relationship to
Campylobacter jejuni infection. Ann Neurol 38(5):809–816
3. Winer JB, Hughes RA, Greenwood RJ, Perkin GD, Healy MJ
(1985) Prognosis in Guillain-Barre´ syndrome. Lancet
1(8439):1202–1203
4. Sharshar T, Chevret S, Bourdain F, Raphae¨l JC (2003) French
Cooperative Group on Plasma Exchange in Guillain-Barre´ Syn-
drome. Early predictors of mechanical ventilation in Guillain-
Barre´ syndrome. Crit Care Med 31(1):278–283 (PubMed PMID:
12545029)
5. Yuki N, Hartung HP (2012) Guillain-Barre´ syndrome. N Engl J
Med 366(24):2294–2304
6. van den Berg B, Walgaard C, Drenthen J, Fokke C, Jacobs BC,
van Doorn PA (2014) Guillain-Barre´ syndrome: pathogenesis,
diagnosis, treatment and prognosis. Nat Rev Neurol
10(8):469–482
7. Willison HJ, Jacobs BC, van Doorn PA (2016) Guillain-Barre´
syndrome. Lancet 388(10045):717–727
8. van der Meche´ FG (1992) Schmitz PI. A randomized trial com-
paring intravenous immune globulin and plasma exchange in
Guillain-Barre´ syndrome. Dutch Guillain-Barre´ Study Group.
N Engl J Med 326(17):1123–1129
9. Hughes RA, Swan AV, van Doorn PA (2014) Intravenous
immunoglobulin for Guillain-Barre´ syndrome. Cochrane Data-
base Syst Rev. (9):CD002063. doi: 10.1002/14651858.
CD002063.pub6
10. Raphae¨l JC, Chevret S, Hughes RA, Annane D (2012) Plasma
exchange for Guillain-Barre´ syndrome. Cochrane Database Syst
Rev. 7:CD001798. doi:10.1002/14651858.CD001798.pub2 (Re-
view. PubMed PMID: 22786475)
11. Ng KKP, Howard RS, Fish DR, Hirsch NP, Wiles CM, Murray
NMF, Miller DH (1995) Management and outcome of severe
Guillain-Barre´ syndrome. Q J Med 88(4):243–250
12. Henderson RD, Lawn ND, Fletcher DD, McClelland RL, Wij-
dicks EF (2003) The morbidity of Guillain-Barre´ syndrome
admitted to the intensive care unit. Neurology. 60(1):17–21
13. Dhar R, Stitt L, Hahn AF (2008) The morbidity and outcome of
patients with Guillain-Barre´ syndrome admitted to the intensive
care unit. J Neurol Sci 264(1–2):121–128
14. Netto AB, Taly AB, Kulkarni GB, Rao UG, Rao S (2011)
Mortality in mechanically ventilated patients of Guillain Barre´
Syndrome. Ann Indian Acad Neurol. 14(4):262–266
15. Netto AB, Taly AB, Kulkarni GB, Uma Maheshwara Rao GS,
Rao S (2011) Prognosis of patients with Guillain-Barre´ syndrome
requiring mechanical ventilation. Neurol India 59(5):707–711
16. Hughes RA, Wijdicks EF, Benson E, Cornblath DR, Hahn AF,
Meythaler JM, Sladky JT, Barohn RJ, Stevens JC (2005) Mul-
tidisciplinary Consensus Group Supportive care for patients with
Guillain-Barre´ syndrome. Arch Neurol 62(8):1194–1198
17. Fletcher DD, Lawn ND, Wolter TD, Wijdicks EF (2000) Long-
term outcome in patients with Guillain-Barre´ syndrome requiring
mechanical ventilation. Neurology 54(12):2311–2315
18. Damian MS, Ben-Shlomo Y, Howard R, Bellotti T, Harrison D,
Griggs K, Rowan K (2013) The effect of secular trends and
specialist neurocritical care on mortality for patients with
intracerebral haemorrhage, myasthenia gravis and Guillain-Barre´
syndrome admitted to critical care: an analysis of the Intensive
Care National Audit & Research Centre (ICNARC) national
United Kingdom database. Intensive Care Med 39(8):1405–1412
19. Witsch J, Galldiks N, Bender A, Kollmar R, Bo¨sel J, Hobohm C,
Gu¨nther A, Schirotzek I, Fuchs K, Ju¨ttler E (2013) Long-term
outcome in patients with Guillain-Barre´ syndrome requiring
mechanical ventilation. J Neurol 260(5):1367–1374
20. Ali MI, Ferna´ndez-Pe´rez ER, Pendem S, Brown DR, Wijdicks
EF, Gajic O (2006) Mechanical ventilation in patients with
Guillain-Barre´ syndrome. Respir Care. 51(12):1403–1407
21. McKhann GM, Cornblath DR, Griffin JW, Ho TW, Li CY, Jiang
Z, Wu HS, Zhaori G, Liu Y, Jou LP et al (1993) Acute motor
axonal neuropathy: a frequent cause of acute flaccid paralysis in
China. Ann Neurol. 33(4):333–342
22. Hadden RD, Cornblath DR, Hughes RA, Zielasek J, Hartung HP,
Toyka KV et al (1998) Electrophysiological classification of
Guillain-Barre´ syndrome: clinical associations and outcome.
Plasma exchange/sandoglobulin Guillain-Barre´ Syndrome Trial
Group. Ann Neurol 44(5):780–788
23. Kuwabara S, Yuki N (2013) Axonal Guillain-Barre´ syndrome:
concepts and controversies. Lancet Neurol 12(12):1180–1188
24. Visser LH, Schmitz PI, Meulstee J, van Doorn PA, van der
Meche´ FG (1999) Prognostic factors of Guillain-Barre´ syndrome
after intravenous immunoglobulin or plasma exchange. Dutch
Guillain-Barre´ Study Group. Neurology 53(3):598–604
25. Chio` A, Cocito D, Leone M, Giordana MT, Mora G, Mutani R
(2003) Piemonte and Valle d’Aosta Register for Guillain-Barre´
Syndrome. Guillain-Barre´ syndrome: a prospective, population-
based incidence and outcome survey. Neurology.
60(7):1146–1150
J Neurol (2017) 264:564–569 569
123
